Merck & Company (MRK) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Merck & Company (MRK)

124.03

+0.49 (0.40%)

as of Jul 13, 2026, 8:00:00 pm Market Open.

311 watching

Investor Insights

Jul 13, 2026, 12:00 am

This summary was created by AI, based on 22 opinions in the last 12 months.

Merck & Company (MRK) is regarded as a strong investment opportunity, primarily due to its robust drug pipeline and significant growth potential despite challenges with its blockbuster drug, Keytruda, which is set to go off-patent in 2028. Analysts highlight the company's anticipated increase in sales, particularly from Keytruda and other new drugs in development. While some concerns exist regarding market fluctuations and pricing clarity, a substantial number of experts maintain an optimistic outlook on the stock's performance. With a promising array of drugs poised for release by 2030 and solid financial metrics, including rising cash reserves and share buybacks, MRK is projected to see continued growth, making it a compelling choice for healthcare investors. Expert recommendations suggest a prudent approach to stop-loss levels and target price adjustments.

Consensus

Bullish

Valuation

Undervalued

Similar

Pfeizer, PFE

BUY

At a 5 year low. Have some good products. At a good price.

WEAK BUY

Expiring patents have created problems. Pipeline is not as strong as other pharmaceuticals, but the price is very cheap.

TOP PICK

One of the cheapest in the drug sctor.

DON'T BUY

Losing a lot of their patents with nothing new in the pipeline.

WEAK BUY

No earnings growth this year. Should be some in 2003. At a good price. Prefers J&J or Pfizer.

DON'T BUY

Broke through a technical base. Generics are giving some tough competition.

DON'T BUY

A lot of their drugs have come off patent without adequate replacement. Prefers Pfizer.

WAIT

Competition. Pipeline is weak now. OK long term.

DON'T BUY

Pharmaceuticals may be re-establishing themselves for market leadership. Prefers Lily and Abbot

DON'T BUY

Has been a defensive stock. Overvalued.

DON'T BUY

Patent expiries are a concern. Limited pipeline. Arthritis drug not moving well. Prefers Pfizer.

BUY

Likes both Pfizer and Merck in pharmaceuticals.

BUY

Just came off a good technical support.

BUY

Good, but has some patent expiries.

DON'T BUY

Not a fan at this time. Patent expiries coming up. Prefers Pfizer.

Showing 286 to 300 of 305 entries

Most Recent Experts

Jim Cramer - Mad Money

CNBC

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Dan Rohinton

iA Global Asset Management

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Merck & Company (MRK)